menu
    • menu
    [{"orgOrder":0,"company":"Enleofen Bio Pte","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BI 765423","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Enleofen Bio Pte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enleofen Bio Pte \/ Enleofen Bio Pte","highestDevelopmentStatusID":"6","companyTruncated":"Enleofen Bio Pte \/ Enleofen Bio Pte"},{"orgOrder":0,"company":"Enleofen Bio Pte","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Enx108A","moa":"IL-11 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Enleofen Bio Pte","amount2":1,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Enleofen Bio Pte \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"5","companyTruncated":"Enleofen Bio Pte \/ Boehringer Ingelheim GmbH"}]

    Find Clinical Drug Pipeline Developments & Deals by Enleofen Bio Pte

    Menu

    Enleofen Bio Pte

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enleofen Bio Pte

                            Singapore arrow
                            Peptide Process CMC
                            Not Confirmed

                            Enleofen Bio Pte

                            Singapore arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BI 765423

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

                            Details : BI 765423 is the first-in-class IL-11 inhibitor antibody, which is being developed in partnership with Enleofen for the treatment of fibrotic diseases.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 05, 2023

                            Lead Product(s) : BI 765423

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enleofen Bio Pte

                            Singapore arrow
                            Peptide Process CMC
                            Not Confirmed

                            Enleofen Bio Pte

                            Singapore arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enx108A

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : IND Enabling

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $1,000.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibr...

                            Details : Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : $1,000.0 million

                            September 01, 2020

                            Lead Product(s) : Enx108A

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : IND Enabling

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $1,000.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth